Know more

About cookies

What is a "cookie"?

A "cookie" is a piece of information, usually small and identified by a name, which may be sent to your browser by a website you are visiting. Your web browser will store it for a period of time, and send it back to the web server each time you log on again.

Different types of cookies are placed on the sites:

  • Cookies strictly necessary for the proper functioning of the site
  • Cookies deposited by third party sites to improve the interactivity of the site, to collect statistics

Learn more about cookies and how they work

The different types of cookies used on this site

Cookies strictly necessary for the site to function

These cookies allow the main services of the site to function optimally. You can technically block them using your browser settings but your experience on the site may be degraded.

Furthermore, you have the possibility of opposing the use of audience measurement tracers strictly necessary for the functioning and current administration of the website in the cookie management window accessible via the link located in the footer of the site.

Technical cookies

Name of the cookie

Purpose

Shelf life

CAS and PHP session cookies

Login credentials, session security

Session

Tarteaucitron

Saving your cookie consent choices

12 months

Audience measurement cookies (AT Internet)

Name of the cookie

Purpose

Shelf life

atid

Trace the visitor's route in order to establish visit statistics.

13 months

atuserid

Store the anonymous ID of the visitor who starts the first time he visits the site

13 months

atidvisitor

Identify the numbers (unique identifiers of a site) seen by the visitor and store the visitor's identifiers.

13 months

About the AT Internet audience measurement tool :

AT Internet's audience measurement tool Analytics is deployed on this site in order to obtain information on visitors' navigation and to improve its use.

The French data protection authority (CNIL) has granted an exemption to AT Internet's Web Analytics cookie. This tool is thus exempt from the collection of the Internet user's consent with regard to the deposit of analytics cookies. However, you can refuse the deposit of these cookies via the cookie management panel.

Good to know:

  • The data collected are not cross-checked with other processing operations
  • The deposited cookie is only used to produce anonymous statistics
  • The cookie does not allow the user's navigation on other sites to be tracked.

Third party cookies to improve the interactivity of the site

This site relies on certain services provided by third parties which allow :

  • to offer interactive content;
  • improve usability and facilitate the sharing of content on social networks;
  • view videos and animated presentations directly on our website;
  • protect form entries from robots;
  • monitor the performance of the site.

These third parties will collect and use your browsing data for their own purposes.

How to accept or reject cookies

When you start browsing an eZpublish site, the appearance of the "cookies" banner allows you to accept or refuse all the cookies we use. This banner will be displayed as long as you have not made a choice, even if you are browsing on another page of the site.

You can change your choices at any time by clicking on the "Cookie Management" link.

You can manage these cookies in your browser. Here are the procedures to follow: Firefox; Chrome; Explorer; Safari; Opera

For more information about the cookies we use, you can contact INRAE's Data Protection Officer by email at cil-dpo@inrae.fr or by post at :

INRAE

24, chemin de Borde Rouge -Auzeville - CS52627 31326 Castanet Tolosan cedex - France

Last update: May 2021

Menu Logo Principal logo Université Clermont Auvergne & associés

Human Nutrition Unit

Zone de texte éditable et éditée et rééditée

To prevent and predict

     
From the identification of muscle loss biomarkers and protein malnutrition to interventional strategies to preserve organ function



    Identify biomarkers of muscle atrophy in humans
Muscle loss is an aggravating factor of several pathologies. However, no predictive tool exists for its early detection while it is almost impossible to revert muscle atrophy when it is established. 
Click to read more

 


Our goal is to identify biomarkers witnessing the development of muscle atrophy independently of the pathology. As a first step, we have identified 238 markers in skeletal muscles that are specifically over or under expressed during lung cancer or chronic kidney disease.

Our current studies focus on the identification of blood markers highly linked to the development of muscle atrophy. Our final goal is the development of a tool dedicated to routine detection of a catabolic situation in hospitals and/or to the follow-up of anabolic treatments.

To provide an integrative view of muscle aging in human, we combine proteomics, transcriptomics, immunohistology and molecular imaging to study sub-cohorts of elderly subjects without/with age-related pathologies. Using these methodologies, we identified potential biomarkers of muscle aging, and describe age/pathologies-related alterations in muscle fiber metabolism, lipid droplets, apoptosis, capillarization, satellite cells and fibrosis.

Investigators
Julien Aniort, Daniel Béchet, Agnès Claustre, Cécile Coudy-Gandilhon, Anne-Elisabeth Heng, Cécile Polge, Daniel Taillandier

 




    Identification of predictive epigenetic marks of predisposition to the development of obesity
Context
Metabolic diseases (obesity, diabetes, etc.) are rising to dramatic proportions worldwide, making them a major public health issue. These pathologies are largely due to environmental causes, among which disorders associated with our lifestyle play an important role (diet, sedentary lifestyle, stress, etc.).
Click to read more
However, all individuals are not equal when faced with environmental stresses and an individual's predisposition to the development of obesity results from interactions between one' s intrinsic predisposition and the environment. While genetic factors seem to play only a limited role, numerous epidemiological studies report that nutrition during the perinatal period is an important determinant of the individual's health status throughout life. These observations have led to the concept of Developmental Origins of Health and Disease (DOHaD). Thus, it has been shown (mainly by Barker et al.) that a maternal nutritional stress can result in specific adaptations in the fetus leading to an impairment of its physiology and metabolism and an increased predisposition to metabolic diseases in adulthood.
Identification of early predictive markers of obesity predisposition
Experimental models in rodents have shown that the imprints of the maternal environment can be epigenetic. The term epigenetics describes stable alterations in gene expression that do not involve any change in the DNA sequence. Epigenome development takes place during development, is strongly influenced by the environment, and is maintained through mitosis. The main epigenetic processes involved in the regulation of gene expression are the DNA methylation , post-translational modifications of histones and deregulated expression of small non-coding RNAs (in particular microRNAs: miRNAs).
We hypothesize that epigenetic imprints, occurring very early in development, can be considered as early predictive markers of susceptibility to the development of metabolic diseases.
Thus, we set up experimental nutritional models in mice, resulting in opposite obesity predisposition phenotypes (sensitive vs. resistant to the development of obesity). From these models, our project consists in identifying predictive epigenetic markers (DNA methylation and miRNA) specifically correlated to the observed metabolic phenotypes and having a predictive value, i.e. detectable before the appearance of clinical signs.
On the long term, our objective is to evaluate in humans all the previously identified epigenetic marks so that we can draw up a predictive test of predisposition to obesity to propose, before any clinical signs and any alteration of physiological indicators, a preventive treatment.

References

Investigators
Pierre Fafournoux, Céline Jousse, Laurent Parry